#USA #Cancer Treatment #National Harbor #HanchorBio #HCB301

HanchorBio Announces Presentation at SITC 2025

HanchorBio, a biotechnology company based in Taipei, Shanghai, and the San Francisco Bay Area, recently made an exciting announcement regarding its innovative cancer treatment, HCB301. This clinical-stage company, dedicated to developing next-generation multi-specific immunotherapies, revealed that the abstract detailing preclinical data on HCB301 has been accepted for a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. This prestigious event will take place from November 5 to 9, 2025, in National Harbor, Maryland.

The significance of having an abstract accepted for presentation at SITC cannot be overstated. This gathering is recognized as the largest annual conference worldwide focused exclusively on cancer immunotherapy. Each year, a substantial number of abstracts—over 1,300—get submitted, with each work evaluated against stringent selection criteria that assess research quality, innovativeness, and the potential to advance the field of cancer immunotherapy.

Presentation of Innovative Research

The accepted abstract, titled “A Novel Tri-Specific Fc Fusion Protein Targeting PD-L1, CD47, and TGFβ Remodels the Tumor Microenvironment and Enhances Anti-Tumor Immunity,” is set to be presented on Saturday, November 8, 2025. This presentation will underscore preclinical efficacy and safety data that support the potential of HCB301 as a pioneering immune-enhancing biologic, specifically targeting critical mechanisms by which tumors evade immune detection.

Wenwu Zhai, the Chief Scientific Officer of HanchorBio, expressed pride in the acceptance, stating, “We are honored to present these compelling preclinical data at SITC 2025. HCB301 exemplifies the power of our FBDB™ platform to rationally design multi-specific biologics that restore immune activity and deliver enhanced anti-tumor responses.”

A Closer Look at HCB301

HCB301 represents a tri-functional IgG4 Fc fusion protein comprised of:

• - An anti-PD-L1 antibody
• - A high-affinity SIRPα variant that disrupts CD47-mediated “don’t eat me” signaling
• - A TGF-βRII trap domain

Currently, HCB301 is advancing through a Phase 1 multi-regional clinical trial in the United States and Taiwan, aiming to evaluate its safety, tolerability, and anti-tumor activity in patients diagnosed with advanced solid tumors.

In preliminary studies, HCB301 displayed impressive results by demonstrating:

• - Potent blockade of PD-L1 and TGF-β signaling pathways
• - Effective phagocytosis of CD47+ tumor cells in vitro, coupled with minimal binding to red blood cells, pointing to a potentially improved safety profile compared to other CD47-targeting agents
• - Comparable in vivo efficacy to a combination of three agents across various xenograft models

Furthermore, the abstract will be published in the Journal for ImmunoTherapy of Cancer (JITC) in February 2026, as part of the SITC 2025 Final Supplement, ensuring broader visibility for HCB301's promising advancements in immunotherapy.

About HanchorBio

HanchorBio stands out in the landscape of biotechnology companies due to its commitment to reactivating the immune system to combat a range of diseases, particularly cancer. Driven by a team of experienced professionals from the pharmaceutical industry, the company showcases a potential for impactful innovations in the arena of immune-oncology. For more details on their ongoing projects and research, visit HanchorBio’s website.

This announcement marks a significant milestone for HanchorBio and highlights its advancing role in the fight against cancer through innovative treatment strategies. With the upcoming presentation at SITC, the spotlight will be on HCB301’s potential to significantly enhance cancer treatment paradigms.